secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0000200406-24-000088
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Johnson & Johnson Q3 sales up 5.2% to $22.5B; GAAP EPS down 34% to $1.11 on higher R&D and other charges
--------------------------------------------------------------------------------

- Worldwide sales $22.47B (+5.2% reported, +6.3% operational); MedTech up 5.8%, Innovative Medicine up 4.9%.
- GAAP net earnings from continuing ops $2.69B ($1.11 diluted EPS), down 37.5% YoY; adjusted net earnings $5.88B ($2.42 adjusted EPS), down 13.3%.
- R&D expense jumped 43.7% to $4.95B (22.0% of sales); other expense net $1.80B vs $0.50B in prior year.
- GAAP effective tax rate 19.3% vs 17.4%; adjusted tax rate 19.3% vs 15.6%.
- Discontinued ops had no contribution vs $21.7B in prior year (related to Kenvue separation).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040624000088/0000200406-24-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040624000088/jnj-20241015.htm
  HTML page:      https://secwatch.observer/filing/0000200406-24-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer